Global Dry Eye Syndrome Treatment Market Report 2022 to 2028: Featuring AbbVie, Novartis, Sun Pharmaceuticals Industries and OASIS Medical Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Syndrome Treatment Market Size, Share & Industry Trends Analysis Report by Type, Drug, Dosage, Distribution Channel, Sales Channel, Product, Regional Outlook and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.

The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.

For clear eyesight, the tear film is crucial. Three layers comprise the tear film: an oily layer, a watery layer, and a mucus layer with each layer having a specific function. The exterior of the tear film is the oily layer. It smoothens the tear’s surface and slows down the rate of drying.

The meibomian glands in the eye produce this layer. The center of the tear film is the watery layer. The majority of what is perceived as tears is made up of them. By removing foreign objects from the eye, this layer cleanses the eye. The lacrimal glands present in eyelids produce this layer.

The innermost layer of the film is called the mucus layer. This aids in distributing the watery layer and maintaining the eye’s moisture.

Tears would not adhere to the eye without mucus, which is produced by the conjunctiva. This is the transparent tissue that lines the interior of the eyelids and the surface of the eye. Normal tear production keeps eyes moist all the time. The eyes produce a lot of tears when they are inflamed or when someone cries.

Market Growth Factors

Development of promising drugs to manage Dry Eye Diseases

In various age categories, the estimated concentration ranges from roughly 5% to over 35%. Dry eye (DE) is usually overlooked despite being very common. Dry Eye is a significant burden on the public healthcare system because of its detrimental effects on patients’ visual function and life quality.

Therefore, efforts to improve diagnostic procedures and develop suitable DE treatments are merited. Reproxalap (Alderya Therapeutics), tivanisiran (Sylentis), tanfanercept (HanAll BioPharma), timbetasin (Regenerx), loteprednol etabonate (Kala Pharma), and NOV03 (Bausch + Lomb) are few of the medications that were recently investigated in Phase 3 trials for the treatment of dry eyes. As these development continue to proceed, they aid in the expansion of the dry eye syndrome treatment market.

Availability of different procedures and medicines to suit the majority

Burning, Itching, irritation, eye tiredness, and ocular inflammation are among the prominent symptoms of DED, which can vary from mild to serious and can potentially cause impairment to the cornea, conjunctiva, and even loss of eyesight.

As a result, the treatment must be customized to each patient by focusing on the distinct mechanisms linked to their condition, depending on the various presentations and pathophysiology. The tailoring of the medical procedure allows patients to think about the pros and cons before going for treatment.

This provides satisfaction and additional comfort to patients which tremendously helps in the success of treatment. This, in turn, will bolster the growth of the dry eye syndrome treatment market.

Market Restraining Factors

Drug approval takes a longer time

Drug approval entails several expensive regulatory approvals and research phases. About four steps of clinical trials are involved in the drug approval process, as well as different stages of screening by regulatory agencies like the FDA. Because clinical trial phases need significant investments, the costs of unsuccessful trials are also large.

For instance, a Forbes article estimates that a drug manufacturer spends roughly $350 million on each treatment before it is introduced to the market. This demonstrates significant drug approval costs that are expected to have an impact on the market for dry eye medications. Additionally, long waiting times also add up to lost money for these manufacturers, and as such hampers the growth of the dry eye syndrome treatment market.

Scope of the Study

Market Segments Covered in the Report:

By Type

• Evaporative Dry Eye Syndrome
• Aqueous Deficient Dry Eye Syndrome

By Drug

• Restasis
• Xiidra
• Cequa
• Eysuvis
• Tyrvaya & Others

By Dosage

• Eye drops
• Gels
• Capsules & Tablets
• Eye Solutions
• Ointments

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By Sales Channel

• OTC
• Prescription

By Product

• Cyclosporine
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
• Oral Omega Supplements
• Others

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Johnson & Johnson (Johnson & Johnson Services, Inc.)
• AbbVie, Inc.
• Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
• Novartis AG
• Sun Pharmaceuticals Industries Ltd.
• AFT Pharmaceuticals
• Santen Pharmaceutical Co., Ltd.
• Oyster Point Pharma, Inc.
• OASIS Medical, Inc.
• Otsuka Pharmaceutical Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/hicmir

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900